比索洛尔联合丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛的临床研究  

Clinical study on bisoprolol combined with Sulfotanshinone Sodium Injection in treatment of unstable angina

作　　者：邵峰[1] 辜裕光 吴华雄[2] 

机构地区：[1]深圳市第二人民医院药学部,广东深圳518035 [2]深圳市第二人民医院心内科,广东深圳518035

出　　处：《现代药物与临床》2017年第6期1025-1028,共4页Drugs & Clinic

摘　　要：目的探讨富马酸比索洛尔片联合丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛的临床疗效。方法选取2016年1月—2016年12月在深圳市第二人民医院接受治疗的不稳定型心绞痛患者84例,采用计算机随机分组法分为对照组和治疗组,每组各42例。对照组静脉滴注丹参酮ⅡA磺酸钠注射液,80 mg加入到0.9%氯化钠注射液250 m L中,1次/d。治疗组在对照组基础上口服富马酸比索洛尔片,5 mg/次,1次/d。两组患者均治疗14 d。观察两组的临床疗效,比较两组的心电图改善和血清细胞因子情况。结果治疗后,对照组和治疗组的总有效率分别为70.95%、95.24%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组和治疗组的心电图改善率分别为83.33%、97.26%,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清白细胞介素-6(IL-6)、可溶性CD40配体(s CD40L)、妊娠相关血浆蛋白A(PAPP-A)和心肌肌钙蛋白I(CTn I)水平均显著下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论富马酸比索洛尔片联合丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛具有较好的临床疗效,可明显改善患者临床症状,降低血清细胞因子水平,具有一定的临床推广应用价值。Objective To evaluate the clinical efficacy of Bisoprolol Fumarate Tablets combined with Sulfotanshinone Sodium Injection in treatment of unstable angina. Methods Patients （84 cases） with unstable angina in Shenzhen Second People＇s Hospital from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Sulfotanshinone Sodium Injection, 80 mg added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Bisoprolol Fumarate Tablets on the basis of the control group, 5 mg/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and electrocardiogram improvement and serum cytokines in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 70.95% and 95.24%, respectively, and there was difference between two groups （P 〈 0.05）. After treatment, the electrocardiogram improvement rate in the control and treatment groups were 83.33% and 97.26%, respectively, and there was difference between two groups （P 〈 0.05）. After treatment, the levels of IL-6, sCD40L, PAPP-A, and CTnI in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Bisoprolol Fumarate Tablets combined with Sulfotanshinone Sodium Injection has clinical curative effect in treatment of unstable angina, can improve clinical symptoms, and decrease serum cytokines, which has a certain clinical application value.

关 键 词：富马酸比索洛尔片 丹参酮ⅡA磺酸钠注射液 不稳定型心绞痛 心电图改善率 白细胞介素-6 

分 类 号：R972[医药卫生—药品]